I. FINANCING OF PRIVATE BIOTECHNOLOGY COMPANIES: $311.05M |
||||
Company | Location | Date | Amt. (M) | Details |
| | ||||
Biopsytec | Berlin | 6/28 | €5 (US$4.9) | Biopsytec raised more than US$4.9M in a second round of financing led by SAM Sustainability Private Equity LP; other investors were Deutsche Venture Capital and Industrie Management Holdings |
Cellectis SA | Paris | 6/25 | €16 (US$15.7) | Cellectis completed a second round of financing, raising €16M (US$15.7M); investors included BankInvest BioMedical Venture, AGF Private Equity, funds managed by LCF Rothschild Asset Management, and Odyssee Venture |
Centagenetix | Cambridge, Mass. | 6/17 |
| Centagenetix received a $1.8M credit facility from the Technology and Life Sciences Division of Comerica Inc. |
Enanta | Watertown, Mass. | 6/13 | $18 | Enanta raised $18M in a Series E financing |
Favrille Inc. | San Diego | 6/11 | $16.9 | Favrille raised $16.9M in a financing led by Sanderling Ventures; other investors were De Novo Ventures, Indofin NV, Lotus BioScience Investment Holdings Ltd., Forward Ventures and Alloy Ventures |
FeRx Inc. | San Diego | 6/6 | $15 | FeRx raised $15M in a private placement led by Johnson & Johnson Development Corp. and G.E. Capital's Capital Funding group; other investors were Elan International Services Ltd., Brentwood Associates VIII LP and California Technology Ventures LLC |
Infinity | Boston | 6/24 | $70 | Infinity raised $70M in a Series B financing led by Advent Venture Partners; other investors were Venrock Associates, Prospect Venture Partners, Vulcan Ventures Inc., HBM Bioventure Ltd., Novartis Bioventure Fund, Wellcome Trust Ltd., Tallwood LP, Lotus BioScience Investment Holding, Alexandria Equities LLC, Stelios Papadopoulos, and two company founders; Three Crowns Capital served as placement agent |
MacroGenics | Rockville, Md. | 6/6 | $12.6 | MacroGenics raised $12.6M in a financing led by InterWest Partners; other investors were MPM Capital, OrbiMed Advisors LLC, STARTech Early Ventures, Cogene Biotech Ventures, Hunt Ventures and Alexandria Realty Equities |
Meristem Therapeutics | Clermont-Ferrand, France | 6/27 | €21.15 (US$20.7) | Meristem raised US$20.7M in a fourth financing round; investors were AGF Private Equity, Antin Innovation, CPR Private Equity, Innoven Parten- aires, La Compagnie Financiere de Rothschild, Odyssee Venture, Pechel Industries, SPEF, Banexi Ventures Partners, BNP Private Equity, Tethys, 3i, Sofimac and Sofipar |
Odyssey Pharmaceuticals | San Ramon, Calif. | 6/25 | $15 | Odyssey raised $15M in a Series B financing led by HBM Partners; other investors were Burrill & Co., HealthCap, Cogene Biotech and Incyte Genomics |
Proteome | Cobham, UK | 6/12** | 2.6 (US$3.8) | Proteome Sciences raised US$3.8M in an institutional placing |
RxKinetix Inc. | Louisville, Colo. | 6/21 | $2.75 | RxKinetix raised $2.75M in a private financing; investors were Aweida Ventures Management, MedVenture Associates and Elan Corp. plc |
Salmedix Inc. | San Diego | 6/20 | $27.5 | Salmedix raised $27.5M in a Series B financing; investors were CMEA Ventures Life Sciences, Delphi Ventures, Aberdare Ventures, BioFrontier Global Investments, GeneChem Therapeutics Venture Fund, ProQuest Investments, Ventures West, InterWest Partners, Versant Ventures and Alexandria Equities |
Scynexis Inc. | Cambridge, UK | 6/20 | $29 | Scynexis raised $29M in a private financing with U.S. and European venture funds; investors included Alta Partners, Burrill & Company, SR One, CDC Innovation Partners, KBL Healthcare Ventures, Genavent, SG Asset Management and Ventech |
TopoTarget | Copenhagen, Denmark | 6/12** | DKK120 (US$15.3) | TopoTarget raised US$15.3M in new funding, from HealthCap and BankInvest |
XenoPort Inc. | Santa Clara, Calif. | 6/3 | $43.9 | XenoPort raised $43.9M in a Series C financing led by HBM BioVentures AG; new investors were Lilly BioVentures, Lotus BioScience Ventures, Novartis BioVentures Ltd., and The Invus Group; repeat investors were Arch Venture Partners, CMEA Ventures, Frazier & Co., Lombard Odier & Cie, OrbiMed Advisors, Skyline Ventures and Venrock Associates |
II. MILESTONE PAYMENTS AND EQUITY INVESTMENTS FROM EXISTING CORPORATE PARTNERS: $37.2M | ||||
Company | Partner | Amt. | Triggering | Details (Date) |
| | ||||
Calcigen | Ben Franklin Technology Partners of Northeastern Pennsylvania | ND | Investment | Calcigen received the investment to com- mercialize Calcigen's non-mammalian bio- chemical production technology (6/24) |
Celgene | Novartis Pharma AG (Switzerland) | ND | Milestone payment | Celgene received an undisclosed milestone payment from Novartis for the selection of a selective estrogen receptor modulator preclinical candidate as part of the December 2000 osteoporosis collaboration (6/20) |
Genmab A/S | Hoffmann-La Roche Inc. | $20 | Investment | Roche is investing $20M in Genmab as part of an agreement to expand a year-old deal to create and develop human antibody therapeutics (6/6) |
Ligand Pharmaceuticals Inc. (LGND) | Eli Lilly and Co. | $1.1 | Milestone payment | Ligand earned the $1.1M when Lilly's IND application for LY929 cleared its waiting period (6/5) |
Nastech Pharmaceutical Co. Inc. (NSTK) | Pharmacia Corp. | $2 | Milestone payment | Nastech received a $2M milestone payment under terms of their agreement for intra- nasally administered apomorphine for sexual dysfunction (6/5) |
PG-TXL | Cell Therapeutics Inc. (CTIC) | $1.5 | Milestone payment | Cell Therapeutics made a $1.5M payment to PG-TXL following the completion of Phase II trial enrollment for Xyotax, as well as advan- cing Xyotax to Phase III trials (6/20) |
Neurochem | Picchio Pharma Inc. (Canada) | C$7 (US$4.5) | Investment | Picchio invested US$4.5M in Neurochem through the purchase of 2.8M units (6/19) |
Texas | Schering-Plough Corp. | ND | Milestone payment | Texas Biotechnology received a milestone payment as part of an agreement to discover and develop VLA-4 antagonist drugs to treat asthma (6/19) |
Transition Therapeutics Inc. (Canada; TSE:TTH) | Oncolytics Biotech Inc. (Canada) | C$4.8 (US$3.1) | Investment | Oncolytics acquired about 6.9M shares, or 15%, of Transition Therapeutics for US$3.1M (6/19) |
Vernalis Group | Elan Corp. plc (Ireland) | $5 | Milestone payment | Vernalis received a milestone payment of more than $5M from Elan for the launch of Frova for migraine in the U.S. (6/19) |
Zycos Inc.* | Aventis Pasteur (France) | ND | Milestone payment | Zycos received a milestone payment for discovering antigenic information under a research collaboration initiated in 1999 (6/25) |
| | ||||
Notes: | ||||
# Unless otherwise indicated, shares are traded on the Nasdaq exchange. | ||||
* Denotes privately held company. | ||||
** Denotes the date the item ran in BioWorld International. | ||||
ND = Not disclosed | ||||
CSE = Copenhagen Stock Exchange; LSE = London Stock Exchange; TSE = Toronto Stock Exchange | ||||
